Veterans Affairs' health, benefits app passes 3 million downloads
The app has 1.4 million active users, according to an agency news release Friday on the 81st anniversary of D-Day, which was the Allies' amphibious invasion of German-occupied France.
The app provides veterans access to healthcare and benefits information from their mobile phones, and features fingerprint and face recognition. Users can refill and track VA prescriptions, review appointments, review claims and appeals status, submit evidence for claims and appeals, review VA payment and direct deposit information, locate the closest VA facilities, access the Veterans Crisis Line and show proof of veteran status.
"We encourage all VA-enrolled Veterans to stay connected and informed by downloading the app," Eddie Pool, acting assistant Secretary for Information and Technology and acting chief information officer, said in a news release.
In all, there are 15.8 million veterans, which represents 6.1% of the civilian population 18 year and older. Of those, 7.8 million served in the Gulf War era between 1990 and now, 5.6 million during the Vietnam era from 1950 to 1073, 767,000 during the Korean conflict in the 1940s and 1950s, and less than 120,000 World War II veterans, according to Pew Research in 2023.
As of 2023, 78% of veterans served during wartime.
The Department of Veterans Affairs employs approximately 482,000 people, including 500,000 workers at 170 hospitals and 1,200 local clinics in the nation's largest health care system.
Like with other agencies, the agency is being downsized with plans to cut 83,000 jobs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
4 hours ago
- UPI
RFK Jr.'s plan to overhaul 'vaccine court' system would see opposition
Health and Human Services Secretary Robert F. Kennedy Jr. has long been a critic of the vaccine court, calling it 'biased' against compensating people, slow and unfair. File Photo by Bonnie Cash/UPI | License Photo Aug. 18 (UPI) -- For almost 40 years, people who suspect they've been harmed by a vaccine have been able to turn to a little-known system called the Vaccine Injury Compensation Program -- often simply called the vaccine court. Health and Human Services Secretary Robert F. Kennedy Jr. has long been a critic of the vaccine court, calling it "biased" against compensating people, slow and unfair. He has said that he wants to "revolutionize" or "fix" this system. I'm a scholar of law, health and medicine. I investigated the history, politics and debates about the Vaccine Injury Compensation Program in my book Vaccine Court: The Law and Politics of Injury. Although vaccines are extensively tested and monitored, and are both overwhelmingly safe for the vast majority of people and extremely cost-effective, some people will experience a harmful reaction to a vaccine. The vaccine court establishes a way to figure out who those people are and to provide justice to them. Having studied the vaccine court for 15 years, I agree that it could use some fixing. But changing it dramatically will be difficult and potentially damaging to public health. Deciphering vaccine injuries The Vaccine Injury Compensation Program is essentially a process that enables doctors, lawyers, patients, parents and government officials to determine who deserves compensation for a legitimate vaccine injury. It was established in 1986 by an act of Congress to solve a specific social problem: possible vaccine injuries to children from the whole-cell pertussis vaccine. That vaccine, which was discontinued in the United States in the 1990s, could cause alarming side effects like prolonged crying and convulsions. Parents sued vaccine manufacturers, and some stopped producing vaccines. Congress was worried that lawsuits would collapse the country's vaccine supply, allowing diseases to make a comeback. The National Childhood Vaccine Injury Act of 1986 created the vaccine court process and shielded vaccine manufacturers from these lawsuits. Here's how it works: A person who feels they have experienced a vaccine-related injury files a claim to be heard by a legal official called a special master in the U.S. Court of Federal Claims. The Health and Human Services secretary is named as the defendant and is represented by Department of Justice attorneys. Doctors who work for HHS evaluate the medical records and make a recommendation about whether they think the vaccine caused the person's medical problem. Some agreed-upon vaccine injuries are listed for automatic compensation, while other outcomes that are scientifically contested go through a hearing to determine if the vaccine caused the problem. Awards come from a trust fund, built up through a 75-cent excise tax on each dose of covered vaccine sold. Petitioners' attorneys who specialize in vaccine injury claims are paid by the trust fund, whether they win or lose. Some updates needed Much has changed in the decades since Congress wrote the law, but Congress has not enacted updates to keep up. For instance, the law supplies only eight special masters to hear all the cases, but the caseload has risen dramatically as more vaccines have been covered by the law. It set a damages cap of $250,000 in 1986, but did not account for inflation. The statute of limitations for an injury is three years, but in my research, I found many people file too late and miss their chance. When the law was written, it only covered vaccines recommended for children. In 2023, the program expanded to include vaccines for pregnant women. Vaccines just for adults, like shingles, are not covered. COVID-19 vaccine claims go to another system for emergency countermeasures vaccines that has been widely criticized. These vaccines could be added to the program, as lawyers who bring claims there have advocated. These reform ideas are "friendly amendments" with bipartisan support. Kennedy has mentioned some of them, too. A complex system is hard to revolutionize Kennedy hasn't publicly stated enough details about his plan for the vaccine court to reveal the changes he intends to make. The first and least disruptive course of action would be to ask Congress to pass the bipartisan reforms noted above. But some of his comments suggest he may seek to dismantle it, not fix it. None of his options are straightforward, however, and consequences are hard to predict. Straight up changing the vaccine court's structure would probably be the most difficult path. It requires Congress to amend the 1986 law that set it up and President Donald Trump to sign the legislation. Passing the bill to dismantle it requires the same process. Either direction involves all the difficulties of getting a contentious bill through Congress. Even the "friendly amendments" are hard -- a 2021 bill to fix the vaccine court was introduced but failed to advance. However, there are several less direct possibilities. Adding autism to the injuries list Kennedy has long supported discredited claims about harms from vaccines, but the vaccine court has been a bulwark against claims that lack mainstream scientific support. For example, the vaccine court held a yearslong court process from 2002 to 2010 and found that autism was not a vaccine injury. The autism trials drew on 50 expert reports, 939 medical articles and 28 experts testifying on the record. The special masters deciding the cases found that none of the causation hypotheses put forward to connect autism and vaccines were reliable as medical or scientific theories. Much of Kennedy's ire is directed at the special masters, who he claims "prioritize the solvency" of the system "over their duty to compensate victims." But the special masters do not work for him. Rather, they are appointed by a majority of the judges in the Court of Federal Claims for four-year terms -- and those judges themselves have 15-year terms. Kennedy cannot legally remove any of them in the middle of their service to install new judges who share his views. Given that, he may seek to put conditions like autism on the list of presumed vaccine injuries, in effect overturning the special masters' decisions. Revising the list of recognized injuries to add ones without medical evidence is within Kennedy's powers, but it would still be difficult. It requires a long administrative process with feedback from an advisory committee and the public. Such revisions have historically been controversial, and are usually linked to major scientific reviews of their validity. Public health and medical groups are already mobilized against Kennedy's vaccine policy moves. If he failed to follow legally required procedures while adding new injuries to the list, he could be sued to stop the changes. Targeting vaccine manufacturers Kennedy could also lean on his newly reconstituted Advisory Committee on Immunization Practices to withdraw recommendations for certain vaccines, which would also remove them from eligibility in the vaccine compensation court. Lawsuits against manufacturers could then go straight to regular courts. On Thursday, the Department of Health and Human Services may have taken a step in this direction by announcing the revival of a childhood vaccine safety task force in response to a lawsuit by anti-vaccine activists. Kennedy has also supported legislation that would allow claims currently heard in vaccine court to go to regular courts. These drastic reforms could essentially dismantle the vaccine court. People claiming vaccine injuries could hope to win damages through personal injury lawsuits in the civil justice system instead of vaccine court, perhaps by convincing a jury or getting a settlement. These types of settlements were what prompted the creation of the vaccine court in the first place. But these lawsuits could be hard to win. There is a higher bar for scientific evidence in regular courts than in vaccine court, and plaintiffs would have to sue large corporations rather than file a government claim. Raising the idea of reforming the vaccine court has provoked strong reactions across the many groups with a stake in the program. It is a complex system with multiple constituents, and Kennedy's approaches so far pull in different directions. The push to revolutionize it will test the strength of its complex design, but the vaccine court may yet hold up. Anna Kirkland is a professor of women's and gender studies a the University of Michigan. This article is republished from The Conversation under a Creative Commons license. Read the original article. The views and opinions in this commentary ae solely those of the author.
Yahoo
5 hours ago
- Yahoo
Philips sharpens AI ultrasound push with $150m manufacturing investment
Philips is investing $150m into expanding a pair of US facilities that manufacture its AI-based ultrasound systems and software. Complementing its existing annual $900m US R&D spend, the medtech giant said the funds' allocation towards expanding its Pennsylvania facility that produces ultrasound systems would support its ongoing growth in the US. According to the company, the site currently manufactures transducers but will also work on the configuration of software used in Philips' ultrasound systems in areas such as cardiovascular and maternal care once the expansion is complete. Philips is also allocating a portion of the funds towards expanding its image-guided therapy facility in Minnesota. The Pennsylvania site expansion is expected to add 24,000ft² of manufacturing space and 40,000ft² of storage. The Minnesota site expansion primarily includes the addition of a new medtech training centre, for which the dimensions were unspecified. According to a GlobalData market model, Philips held a 17% share in the US ultrasound systems market in 2024. The figure puts the company in third place, behind rivals GE Healthcare in poll position and Siemens in second place, with US market share of 34% and 29.4%, respectively. Stating that the manufacturing facility expansions reflect Philips' 'deep commitment' to the US, Philips North America chief region leader Jeff DiLullo said: 'Increasing our manufacturing and R&D capabilities will create jobs and accelerate our ability to deliver better care for more people with innovative AI-enabled solutions.' The facility expansions likely also reflect Philips' efforts to future-proof and insulate its operations from the unpredictable nature of US President Donald Trump's tariffs. In particular, his imposition of tariffs on China has fluctuated dramatically throughout the year. Philips has a number of manufacturing sites in the nation, including R&D innovation centres in Shanghai, Suzhou, and Shenzhen. The Dutch business is not the only medtech company to bolster US manufacturing amid tariffs – Thermo Fisher outlaid $2bn worth of investment in April 2025. In an earnings call with investors following the release of its Q2 2025 financials in July, Philips revealed it was revising its expected China-related tariff impacts for 2025 to between €150m-€200m ($175.2m-$233.6m), down from €250m-€300m ($292.1m-$350.5m) previously. Philips CFO Charlotte Hanneman said work on its planned tariff mitigation actions was 'well underway' and on track: 'We've made solid progress on midterm initiatives, including supplier network and manufacturing location optimisation.' According to GlobalData analysis, the use of AI across healthcare is rapidly advancing, with the market projected to reach a $19bn valuation by 2027. Radiology, including ultrasound, has emerged as one of AI's key application areas – chiefly as a way to drive efficiencies and glean insights that human image evaluation could miss. "Philips sharpens AI ultrasound push with $150m manufacturing investment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 hours ago
- Associated Press
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
CHENGDU, China, Aug. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', Stock Code: announced its unaudited interim results for the six months ended 30 June 2025 (the 'Reporting Period'). In the first half of 2025, China's biopharmaceutical industry reached an inflection point for high-quality growth, driven by accelerated innovation in drug research and development, the rollout of favorable policies, increasing momentum in industry collaboration and mergers and acquisitions. Kelun-Biotech capitalized on these opportunities by its proprietary technology platforms, innovation-led R&D, and a well-established commercialization infrastructure. These elements have worked together to enable the Company to establish a fully integrated model covering R&D, clinical development, manufacturing, and commercialization. Focusing on addressing significant unmet medical needs in both oncology (such as breast cancer (BC), non-small cell lung cancer (NSCLC), and gastrointestinal (GI) cancers including gastric cancer (GC) and colorectal cancer (CRC)) and non-oncology diseases, the Company has developed a rich and diverse pipeline of over 30 candidates. More than 10 of these candidates have already entered clinical stage. At the same time, the Company continues to invest in next-generation conjugation technologies and a diversified portfolio of assets, aiming to deliver innovative therapies for patients worldwide and contribute to the improvement of global healthcare. ADC & novel DC assets breakthroughs are redefining the treatment landscape. sac-TMT (sacituzumab tirumotecan, SKB264/MK-2870,佳泰萊®) The first TROP2 ADC drug approved for marketing in LC globally. TNBC: Approved by the National Medical Products Administration ('NMPA') for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies. The Company has initiated a Phase 3 registrational study of sac-TMT monotherapy versus investigator-choice chemotherapy for 1L advanced TNBC. HR+/HER2- BC. In May 2025, the NDA for sac-TMT for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting was accepted by the NMPA, and was included in the priority review and approval process. A Phase 3 registrational study of sac-TMT versus investigator's choice of chemotherapy for treatment of patients with unresectable locally advanced, recurrent or metastatic HR+/HER2- BC who received prior endocrine therapy is in progress. EGFR-mutant NSCLC. In March 2025, the Company received marketing authorization in China from the NMPA for sac-TMT for the treatment of adult patients with EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in ORR, PFS and OS compared with docetaxel. In addition, a Phase 3 registrational study of sac-TMT combined with osimertinib as first-line treatment of locally advanced or metastatic non-squamous EGFR-mutant NSCLC is in progress. EGFR-wild type NSCLC. Two Phase 3 registrational studies of sac-TMT in combination with pembrolizumab are in progress. In June 2025, sac-TMT in combination with tagitanlimab was granted Breakthrough Therapy Designation by the NMPA for the first-line treatment of locally advanced or metastatic non-squamous NSCLC without actionable genomic alterations. Other indications. The Company is actively exploring the potential of sac-TMT both as a monotherapy and in combination with other therapies for treating other solid tumors, including GC, EC, CC, OC, UC, CRPC and HNSCC. Global clinical development. As of August 18, 2025, MSD is progressing 14 ongoing Phase 3 global, multi-center clinical studies for sac-TMT for several types of cancer including BC, LC, gynecological cancer and GI cancer. The Company is also collaborating with MSD on several global Phase 2 basket studies for sac-TMT as monotherapy or in combination with other agents for multiple solid tumors and those studies are ongoing. Trastuzumab Botidotin (HER2 ADC, A166, 舒泰萊®[1]) In January 2025, an NDA for the treatment of adult patients with HER2+ unresectable or metastatic BC who have received at least one prior anti-HER2 therapy was accepted by the CDE of the NMPA. Trastuzumab botidotin has met the primary endpoints of its pivotal Phase 2 trial for 3L+ and advanced HER2+ BC based on results from the primary analysis, and the NDA has been submitted to the NMPA. The Company has initiated an open, multicenter Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase 1 inhibitor ADC. Other ADC Products SKB315 (CLDN18.2 ADC): the company is conducting a Phase 1b clinical trial of SKB315 and have initiated the exploration in combination with immunotherapy for the treatment of GC/GEJC. Results of a Phase 1 study of SKB315 will be presented at 2025 ESMO Congress in October 2025. SKB410/MK-3120 (Nectin-4 ADC): has shown promising Phase 1 clinical data. MSD, as the partner, has launched the global Phase 1/2 clinical trial of SKB410. SKB571/MK-2750: a novel bsADC that primarily targets various solid tumors such as LC and CRC etc. being developed in collaboration with MSD. The Phase 2 clinical trial in China is to be initiated. SKB518, SKB535/MK-6204 and SKB445: novel ADC drugs with potential FIC targets. The Phase 2 clinical trial for SKB518 and the Phase 1 clinical trials for SKB535 and SKB445 are ongoing in China. The Company has entered into a license and collaboration agreement with MSD to develop SKB535. SKB500 and SKB501: novel ADC drugs with verified targets but differentiated payload-linker strategies. The company been received a clinical trial notice approving the IND application of SKB501 and SKB500, respectively, for advanced solid tumors from the NMPA. SKB107: a RDC drug jointly developed by the Company and the Affiliated Hospital of Southwest Medical University (西南醫科大學附屬醫院) targeting bone metastases in solid tumors. In March 2025, an IND application for SKB107 was approved by the NMPA and the Phase 1 study is ongoing. Non-DC asset advancements are diversifying the innovation pipeline. Tagitanlimab (PD-L1 mAb; A167; 科泰莱®): The first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. We have received marketing authorization of tagitanlimab in China from NMPA for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy. In January 2025, we received marketing authorization of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic NPC in China from NMPA. Cetuximab N01 (EGFR mAb; A140; 达泰莱®) An EGFR mAb compared with Cetuximab Solution for Injection (Erbitux®) In February 2025, we received marketing authorization in China from the NMPA for Cetuximab N01 Injection used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of RAS wild-type mCRC. A400/EP0031 (RET inhibitor): The Company is currently conducting pivotal clinical studies for 1L & 2L+ advanced RET+ NSCLC as well as a Phase 1b/2 clinical study for RET+ MTC and solid tumor in China. Through the Company's collaboration and license agreement, Ellipses Pharma is progressing their phase 2 clinical study globally outside of China. SKB378/WIN378 (TSLP mAb): In January 2025, an IND application for SKB378 for the treatment of COPD was approved by the NMPA. The Company's collaboration partner, Windward Bio, has launched the Phase 2 POLARIS trial in patients with asthma. SKB336 (FXI/FXIa mAb): The Phase 1 clinical trial has been completed in China. A296 (STING agonist): A Phase 1 trial is being carried out in China. Commercialization Accelerates: Sales & Market Access Expanding Footprint Sac- TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have been successively launched, marking the full-scale initiation of commercialization. The Company expects to launch trastuzumab botidotin (舒泰莱®) in the China market and file one NDA for A400 in the second half of 2025. Sales performance: The total commercial sales reached RMB309.8 million for the first half of 2025. Among them, the sales of sac-TMT (佳泰莱®) accounted for 97.6%. At the same time, all accounts receivables from sales of pharmaceutical products were collected within the payment period, ensuring efficient and stable cash flow. Market coverage and academic promotion: Currently, the company's businesses have covered 30 provinces, over 300 prefectures, and over 2,000 hospitals, where over 1,000 hospitals generated sales, and reached tens of thousands of healthcare professionals through various types of marketing campaigns to convey product and medical professional information. In addition, the company has obtained authoritative endorsement for its products from experts in clinical guidelines, providing further support for the commercialization process. Commercialization system: The Company has established a fully-fledged marketing team of over 350 people, with a departmental structure that includes marketing, sales, medical affairs, strategic planning and commercial excellence, among other departments, as well as marketing compliance and KA functions. Through the efficient execution of the marketing team, the company has established relationships with multiple leading commercial and distribution groups, including 60+ Tier 1 distributors and 400+ DTP pharmacies. A hierarchical management system for pharmacy retail has been adopted and trainings have been provided to around 4,500 pharmacists in the first half of 2025. By organizing nationwide pharmacy trainings, the company has significantly enhanced the professionalism of terminal services and improved the ability to provide patients with medication guidance. Market access: In the first half of 2025, sac-TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have been included in 29, 25 and 15 provincial networks, respectively, ensuring rapid market access through provincial procurement channels. Meanwhile, preparations for the National Reimburesement Drug List (國家醫保藥品目錄) access of marketed products are underway. Currently, sac-TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have all passed the preliminary formal examination of National Reimbursement Drug List. Meanwhile, to further reduce the burden of patients and implement the concept of inclusive healthcare, the company been proactively facilitating the enrollment of sac-TMT (佳泰莱®) in provincial and prefecture city level Inclusive Insurance (惠民保). As at the end of the Reporting Period, sac-TMT (佳泰莱®) has been enrolled in more than 7 provinces and 20 cities. Global market: Globally, we will continue to pursue a flexible strategy to capture the commercial value in major international markets, through forging synergistic license and collaboration opportunities worldwide. Global Collaboration Network Expansion & Authoritative Industry Recognition In the first half of 2025, the Company continued to expand its global collaboration network and deepen partnerships. Working closely with collaborators, it is advancing clinical research worldwide with the goal of maximizing the global value of its pipeline, delivering high-quality medical solutions to patients, and strengthening its leading position in the biopharmaceutical sector. Collaboration with MSD: As of the date of this announcement, MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as monotherapy or in combination with pembrolizumab or other agents, for several types of cancer including BC, LC, gynecological cancer and GI cancer. In addition to sac-TMT, the Company is also collaborating with MSD on certain ADC assets including SKB410/MK-3120, SKB571/MK-2750, SKB535/MK-6204, etc. to continuously explore favorable ADC pipeline portfolios. Collaboration with Ellipses Pharma: The Company has deepened its collaboration with Ellipses Pharma on A400/EP0031, which has been cleared by the FDA to progress into Phase 2 clinical development. As of June 30, 2025, Ellipses Pharma had set up a total of 36 clinical sites in the United States, Europe and UAE for EP0031. Collaboration with Windward Bio: In January 2025, the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries). In the first half of 2025, the Company earned high recognition from professional institutions and industry associations for its outstanding corporate management, product innovation, and strong performance in the capital market. In May 2025, the Company received 'Asia's Best Company' award from FinanceAsia (亞洲金融), as well as a series of awards from Extel, including 'Most Honored Company', 'Best Company Board', 'Best CEO', 'Best CFO', 'Best ESG' and etc.. The Company was also awarded 'IRM OF CHINESE LISTED COMPANIES' by Securities Times (證券時報). In July 2025, the Company was recognized with the 'China Pharmaceutical Emerging Innovative Force Award' by the China National Pharmaceutical Industry Information Center (中國醫藥工業信息中心). Additionally, the Company continues to strengthen its ESG strategy and improve its ESG governance structure to support sustainable development. The Company has established a comprehensive three-tier ESG governance structure consisting of the Board of Directors, ESG Working Group and ESG Executive Body. Through the establishment and continuous improvement of the ESG governance structure, the Company comprehensively enhances ESG performance ability. Outlook In the second half of 2025, the Company will continue to advance its differentiated pipelines targeting indications with significant medical needs, innovate and optimize payload-linker strategies, novel DC designs and structures, and expand application to non-oncology diseases. Meanwhile, the Company will further enhance its end-to-end drug development capabilities, advance towards commercialization and actively expand global footprints and strategic partnerships to maximize the value of its pipelines. In addition, the Company will continuously optimize its operation system to become a leading global biopharmaceutical company. About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (referred to as 'Kelun-Biotech' Stock Code: is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, production, commercialization, and international collaboration of innovative biotechnology and small-molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with a strategic emphasis on major disease areas such as oncology, autoimmune disorders, inflammation, and metabolic diseases. It is dedicated to building an international platform for drug R&D and industrialization, with the aim of becoming a global leader in the innovative drug sector. Currently, Kelun-Biotech has over 30 key innovative drug projects, including 3 projects that have received market approval, 1 project at the NDA stage, and more than 10 projects in clinical trials. The Company has also successfully established its internationally renowned proprietary ADC development platform, OptiDCTM, with 1 ADC project approved for market launch, 1 ADC project at the NDA stage, and several ADC or novel ADC projects in clinical or preclinical development. For more information, please visit the official website: For further information, please contact: Wonderful Sky Financial Group Ltd. Angie Li & Jason Lai Tel: (852) 6150 8598 / (852) 9798 0715 Email: [email protected] View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
